Jenny Mollen describes “horror movie” side effects from GLP-1 weight-loss drug, citing “blood everywhere”

In a recent interview, actress Jenny Mollen said she microdosed tirzepatide while taking multiple peptides and described severe, unusual side effects.

2 min readEditor-approved Apex article

Actress Jenny Mollen said she experienced what she described as “horror movie” side effects while using a GLP-1 weight-loss medication regimen that included tirzepatide. In the account reported by Page Six on June 24, Mollen tied the effects to her dosing approach, saying she was “microdosing” tirzepatide and also taking a “cocktail of peptides.”

Mollen’s description, as reported, included a striking symptom account. She said she had “blood everywhere,” describing the physical effects of her medication use in graphic terms and contrasting the experience with her expectations. The report attributes the statements to Mollen and frames them as her personal experience.

The same report states that Mollen’s tirzepatide use was part of a broader peptide stack rather than a single drug in isolation. Page Six reports that she was combining tirzepatide, which is commonly associated with GLP-1-based therapies, with other peptides as part of her regimen.

Page Six also characterized tirzepatide as a medication typically used to treat people with diabetes, in addition to its use in weight-loss contexts. However, the report’s central emphasis remains on Mollen’s personal account of side effects while using the drug, including her claim that she was microdosing.

Mollen’s remarks arrive at a time when GLP-1 and other weight-loss medications are increasingly discussed in celebrity and mainstream health conversations. Still, the Page Six report does not include medical documentation or independent confirmation of the specific mechanism behind the symptoms she described, and it presents her comments as a firsthand narrative.

As of publication, no public correction, clarification, or medical follow-up from Mollen was included in the report. Page Six also did not cite statements from a prescribing clinician, a pharmacist, or an independent medical expert in the piece.

If Mollen’s comments are shared more widely, they could contribute to ongoing public discussion about off-label or self-directed dosing practices and the risks of combining prescription medications with other peptides. The report does not indicate what her current treatment plan is, and readers are left without details on her clinical guidance or any subsequent evaluation.

Why It Matters

Celebrity discussion of GLP-1 therapies can influence public perceptions about risk, tolerability, and dosing practices.
If Mollen’s claims are widely repeated, they may renew attention on the safety concerns surrounding nonstandard dosing and multi-peptide combinations.
The Page Six piece does not provide clinical sourcing, leaving uncertainty about underlying causes and highlighting the need for professional medical context.
The episode underscores that serious adverse effects can occur, even when people describe dosing strategies as deliberate or controlled.

Sources

Key Facts

Jenny Mollen told Page Six she used a GLP-1 weight-loss drug regimen that included tirzepatide.
Mollen said she was microdosing tirzepatide.
She also described taking a “cocktail of peptides” alongside tirzepatide.
Mollen said she had severe side effects, describing “blood everywhere.”
The Page Six report frames tirzepatide as commonly used to treat diabetes, while discussing its weight-loss context.
The account is presented as Mollen’s personal experience; the report does not provide independent medical verification.